Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-03-01
2004-07-13
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S279000
Reexamination Certificate
active
06762185
ABSTRACT:
TECHNICAL FIELD
This invention is related to the filed of cancer treatment and therapeutics. More particularly, it relates to compounds and pharmaceutical compositions containing thereof for treating disorders including cancers which are associated with Wnt signaling pathway. It further relates to methods for treating disorders including cancer which are associated with Wnt signaling pathway.
BACKGROUND OF THE INVENTION
Wnt signaling pathway regulates a variety of processes including cell growth, oncogenesis, and development (Moon et al., 1997, Trends Genet. 13, 157-162: Miller et al., 1999, Oncogene 18, 7860-7872: Nusse and Varmus, 1992, Cell 69, 1073-1087: Cadigan and Nusse, 1997, Genes Dev. 11, 3286-3305: Peifer and Polakis, 2000 Science 287, 1606-1609: Polakis 2000, Genes Dev. 14, 1837-1851). Wnt signaling pathway has been intensely studied in a variety of organisms. The activation of TCF4/&bgr;-catenin mediated transcription by Wnt signal transduction has been found to play a key role in its biological functions (Molenaar et al., 1996, Cell 86, 391-399: Gat et al., 1998 Cell 95, 605-614: Orford et al., 1999 J. Cell. Biol. 146, 855-868).
In the absence of Wnt signals, tumor suppressor gene adenomatous polyposis coli (APC) simultaneously interacts with the serine kinase glycogen synthase kinase (GSK)-3&bgr; and &bgr;-catenin (Su et al., 1993, Science 262, 1734-1737: Yost et al., 1996 Genes Dev. 10, 1443-1454: Hayashi et al., 1997, Proc. Natl. Acad. Sci. USA, 94, 242-247: Sakanaka et al., 1998, Proc. Natl. Acad. Sci. USA, 95, 3020-3023: Sakanaka and William, 1999, J. Biol. Chem 274, 14090-14093). Phosphorylation of APC by GSK-3&bgr; regulates the interaction of APC with &bgr;-catenin, which in turn may regulate the signaling function of &bgr;-catenin (B. Rubinfeld et al., Science 272, 1023, 1996). Wnt signaling stabilizes &bgr;-catenin allowing its translocation to the nucleus where it interacts with members of the lymphoid enhancer factor (LEF1)/T-cell factor (TCF4) family of transcription factors (Behrens et al., 1996 Nature 382, 638-642: Hsu et al., 1998, Mol. Cell. Biol. 18, 4807-4818: Roose et all., 1999 Science 285, 1923-1926).
Recently c-myc, a known oncogene, was shown to be a target gene for &bgr;-catenin/TCF4-mediated transcription (He et al., 1998 Science 281 1509-1512: Kolligs et al., 1999 Mol. Cell. Biol. 19, 5696-5706). Many other important genes, including cyclin D1, and metalloproteinase, which are also involved in oncogenesis, have been identified to be regulated by TCF4/bata-catenin transcriptional pathway (Crawford et al., 1999, Oncogene 18, 2883-2891: Shtutman et al., 1999, Proc. Natl. Acad. Sci. USA., 11, 5522-5527: Tetsu and McCormick, 1999 Nature, 398, 422-426).
Moreover, overexpression of several downstream mediators of Wnt signaling has been found to regulate apoptosis (Moris et al., 1996, Proc. Natl. Acad. Sci. USA, 93, 7950-7954: He et al., 1999, Cell 99, 335-345: Orford et al., 1999 J. Cell. Biol., 146, 855-868: Strovel and Sussman, 1999, Exp. Cell. Res., 253, 637-648). Overexpression of APC in human colorectal cancer cells induced apoptosis (Moris et al., 1996, Proc. Natl. Acad. Sci. USA., 93, 7950-7954), ectopic expression of &bgr;-catenin inhibited apoptosis associated with loss of attachment to extracellular matrix (Orford et al, 1999, J. Cell Biol.146, 855-868). Inhibition of TCF4/&bgr;-catenin transcription by expression of dominant-negative mutant of TCF4 blocked Wnt-1-mediated cell survival and rendered cells sensitive to apoptotic stimuli such as anti-cancer agent (Shaoqiong Chen et al., 2001, J. Cell. Biol., 152, 1, 87-96) and APC mutation inhibits apoptosis by allowing constitutive survivin expression, a well-known anti-apoptotic protein (Tao Zhang et al., 2001, Cancer Research, 62, 8664-8667).
Although mutations in the Wnt gene have not been found in human cancer, a mutation in APC or &bgr;-catenin, as is the case in the majority of colorectal tumors, results in inappropriate activation of TCF4, overexpression of c-myc and production of neoplastic growth (Bubinfeld et al, 1997, Science, 275, 1790-1792: Morin et al, 1997, Science, 275, 1787-1790: Casa et al, 1999, Cell. Growth. Differ. 10, 369-376). The tumor suppressor gene (APC) is lost or inactivated in 85% of colorectal cancers and in a variety of other cancers as well (Kinzler and Vogelstein, 1996, Cell 87, 159-170). APC's principal role is that of a negative regulator of the Wnt signal transduction cascade. A center feature of this pathway involves the modulation of the stability and localization of a cytosolic pool of &bgr;-catenin by interaction with a large Axin-based complex that includes APC. This interaction results in phosphorylation of &bgr;-catenin thereby targeting it for degradation.
CREB binding proteins (CBP)/p300 were identified initially in protein interaction assays, first through its association with the transcription factor CREB (Chrivia et al, 1993, Nature, 365, 855-859) and later through its interaction with the adenoviral-transforming protein E1A (Stein et al., 1990, J. Viol., 64, 4421-4427: Eckner et al., 1994, Genes. Dev., 8, 869-884). CBP had a potential to participate in variety of cellular functions including transcriptional coactivator function (Shikama et al., 1997, Trends. Cell. Biol., 7, 230-236: Janknecht and Hunter, 1996, Nature, 383, 22-23). CBP/p300 potentiates &bgr;-catenin-mediated activation of the siamois promoter, a known Wnt target (Hecht et al, 2000, EMBO J. 19, 8, 1839-1850). &bgr;-catenin interacts directly with the CREB-binding domain of CBP and &bgr;-catenin synergizes with CBP to stimulate the transcriptional activation of TCF4/&bgr;-catenin (Ken-Ichi Takemaru and Randall T. Moon, 2000 J. Cell. Biol., 149, 2, 249-254).
From this background, TCF4/&bgr;-catenin and CBP complex of Wnt pathway can be taken as target molecules for the regulation of cell growth, oncogenesis and apoptosis of cells, etc. That is, there is a need for compounds that block TCF4/&bgr;-catenin transcriptional pathway by inhibiting CBP, and therefore can be used for treatment of cancer, especially colorectal cancer.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a compound having general formula (I) as follows:
wherein, R
1
is a bicyclic aryl group having 8 to 11 ring members, which may have 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur, and R
2
is a monocyclic aryl group having 5 to 7 ring members, which may have 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur, and aryl ring in the compound may have one or more substituents selected from a group consisting of halide, hydroxy, cyano, lower alkyl, and lower alkoxy group.
It is an object of the present invention to provide a pharmaceutical composition comprising a safe and effective amount of the compound having general formula (I) and pharmaceutically acceptable carrier, which can be used for treatment of disorders modulated by Wnt signaling pathway, especially by TCF4-&bgr;-catenin-CBP complex.
It is an object of the present invention to provide a method for inhibiting the growth of tumor cells by using the above-described composition of the present invention.
It is an object of the invention to provide a method for inducing apoptosis of tumor cells by using the above-described composition of the present invention.
It is an object of the invention to provide a method for treating a disorder modulated by TCF4-&bgr; catenin-CBP complex by using the above-described composition of the present invention.
It is an object of the present invention to provide a method of treating cancer such as colorectal cancer by administering the composition of the present invention together with other anti-cancer agent such as 5-fluorouracil (5-FU).
REFERENCES:
patent: 5440013 (1995-08-01), Kahn
patent: 5475085 (1995-12-01), Kahn
patent: 5618914 (1997-04-01), Kahn
patent: 5670155 (1997-09-01), Kahn
patent: 5672681 (1997-09-01), Kahn
patent: 5693325 (1997-12-01), Kahn
patent: 5710245 (1998-01-01), Kahn
patent: 5840833 (1998-11-01), Kahn
patent: 5859184 (1999-01-01), Kahn e
Chung Jae Uk
Eguchi Masakatsu
Jeong Kwang Won
Kahn Michael
Moon Sung Hwan
Choongwae Pharma Corporation
Rao Deepak
Seed IP Law Group PLLC
LandOfFree
Compounds useful for treatment of cancer, compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds useful for treatment of cancer, compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds useful for treatment of cancer, compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3214393